600866.SHG Starlake Bioscience Co Inc Zhaoqing Guangdong
- Market cap
- CNY 6.94B
- P/E
- 418.0x
- P/B
- 0.91x
- ROE
- 1.0%
- Dividend yield
- 10.46%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600866.SHG undervalued?
Graham numberThe Graham number of Starlake Bioscience Co Inc Zhaoqing Guangdong cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Starlake Bioscience Co Inc Zhaoqing Guangdong fundamental analysis
No fundamental analysis for Starlake Bioscience Co Inc Zhaoqing Guangdong yet.
Starlake Bioscience Co Inc Zhaoqing Guangdong stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Starlake Bioscience Co Inc Zhaoqing Guangdong
Star Lake Bioscience Co., Inc.Zhaoqing Guangdong engages in the manufacture and selling food additives, feed additives, pharmaceutical intermediates, active pharmaceutical ingredients, organic fertilizers, and bio-based new materials. It operates through three main business lines: food and feed additives, biochemical raw materials and pharmaceutical intermediates, and organic fertilizers. The company offers food additives, including monosodium glutamate, nucleotides, compoun…
Full company profileStarlake Bioscience Co Inc Zhaoqing Guangdong financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Starlake Bioscience Co Inc Zhaoqing Guangdong annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 680M | 687M | 859M | 1.05B | 1.12B | 4.07B | 17.5B | 17.4B | 17.3B | 15.9B | 16.4B |
| Gross Profit | 121M | 29.4M | 200M | 355M | 366M | 795M | 3.00B | 2.40B | 2.94B | 2.63B | 1.56B |
| Operating Income | 17.7M | -132M | 43.5M | 163M | 158M | 284M | 1.43B | 867M | 1.24B | 1.29B | 250M |
| EBITDA | 145M | -39.4M | 138M | 259M | 259M | 470M | 2.67B | 1.90B | 2.18B | 2.15B | 212M |
| Net Income | 24.3M | -158M | 42.3M | 150M | 149M | 152M | 608M | 678M | 943M | 979M | 74.5M |
| EPS | 0.04 | -0.25 | 0.07 | 0.20 | 0.20 | 0.19 | 0.51 | 0.41 | 0.57 | 0.59 | 0.04 |
| Balance Sheet | |||||||||||
| Total Assets | 1.71B | 1.45B | 1.45B | 2.12B | 2.42B | 2.47B | 16.0B | 14.4B | 14.5B | 17.2B | 18.7B |
| Total Liabilities | 638M | 535M | 489M | 596M | 753M | 698M | 9.07B | 6.73B | 6.52B | 8.79B | 10.9B |
| Shareholders' Equity | 1.07B | 914M | 956M | 1.52B | 1.67B | 1.78B | 6.88B | 7.56B | 7.88B | 8.22B | 7.63B |
| Cash & Short-term Investments | 140M | 164M | 97.7M | 265M | 233M | 231M | 1.37B | 1.42B | 1.91B | 2.19B | 1.82B |
| Total Debt | 447M | 345M | 275M | 355M | 401M | 371M | 4.48B | 4.40B | 2.77B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 41.2M | 40.1M | 50.7M | 213M | 250M | 193M | 1.66B | 2.03B | 2.40B | 1.29B | - |
| Capital Expenditure | 40.3M | 40.6M | 33.7M | 157M | 290M | 205M | 452M | 376M | 638M | 2.04B | 1.95B |
| Free Cash Flow | 912K | -560K | 17.0M | 55.8M | -39.9M | -12.5M | 1.21B | 1.65B | 1.76B | -747M | -1.68B |
| Ratios | |||||||||||
| ROE | 2.3% | -17.3% | 4.4% | 9.8% | 8.9% | 8.6% | 8.8% | 9.0% | 12.0% | 11.9% | 1.0% |
| ROA | 1.4% | -10.9% | 2.9% | 7.1% | 6.1% | 6.2% | 3.8% | 4.7% | 6.5% | 5.7% | 0.4% |
| Net Profit Margin | 3.6% | -23.0% | 4.9% | 14.2% | 13.3% | 3.7% | 3.5% | 3.9% | 5.4% | 6.2% | 0.5% |
| Debt to Equity | 0.42x | 0.38x | 0.29x | 0.23x | 0.24x | 0.21x | 0.65x | 0.58x | 0.35x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Starlake Bioscience Co Inc Zhaoqing Guangdong dividends
- Dividend yield
- 10.46%
- Forward dividend
- 0.38 CNY
- Payout ratio
- 74.2%
- Ex-dividend date
- Jul 23, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 727M | 0.44 | 74.2% |
| 2024 | CNY 746M | 0.45 | 79.1% |
| 2023 | CNY 152M | 0.09 | 22.5% |
| 2022 | CNY 368M | 0.31 | 60.4% |
| 2021 | CNY 90.7M | 0.11 | 59.6% |
| 2020 | CNY 16.5M | 0.02 | 11.1% |
| 2019 | CNY 13.6M | 0.02 | 9.1% |
| 2018 | CNY 15.3M | 0.02 | 36.3% |
| 2017 | CNY 32.2M | 0.05 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 135:100 on Nov 28, 2005.
Who owns Starlake Bioscience Co Inc Zhaoqing Guangdong
- Insiders 45.18%
- Institutions 4.38%
- Public & others 50.44%
- Shares outstanding 1.66B
- Free float 997M
Starlake Bioscience Co Inc Zhaoqing Guangdong company profile
- Company name
- Starlake Bioscience Co Inc Zhaoqing Guangdong
- Ticker
- 600866.SHG
- ISIN
- CNE000000H46
- Exchange
- Shanghai Stock Exchange
- Listed since
- Apr 10, 1992
- Sector
- Healthcare
- Industry
- Food Products
- Employees
- 10,528
- Fiscal year end
- December
- Address
- No. 67, Gongnong North Road, Zhaoqing, China, 526040
- Phone
- 86 75 8229 1130
- Website
- starlake.com.cn
About Starlake Bioscience Co Inc Zhaoqing Guangdong
Star Lake Bioscience Co., Inc.Zhaoqing Guangdong engages in the manufacture and selling food additives, feed additives, pharmaceutical intermediates, active pharmaceutical ingredients, organic fertilizers, and bio-based new materials. It operates through three main business lines: food and feed additives, biochemical raw materials and pharmaceutical intermediates, and organic fertilizers. The company offers food additives, including monosodium glutamate, nucleotides, compound seasonings, and corn fermentation products; feed additives such as lysine, threonine, valine, isoleucine, tryptophan, and arginine; pharmaceutical intermediates and active pharmaceutical ingredients including inosine, ribavirin, proline, guanosine, adenosine, adenine, as well as intermediates for AIDS and hepatitis C drugs; and other products, such as organic fertilizers and bio-based materials. The company also provides research, development, and production services in bio-fermentation and chemical synthesis; and engages in the construction and operation of corn deep processing and amino acid projects. In addition, the company offers disodium 5'-guanylate for canned and salted meat, ham, etc. Further, it provides ribavirin, adenosine, adenine, memantine hydrochloride, arginine, D-ribose, fructose syrup, L-valine, L-threonine, L-lysine, etc. Star Lake Bioscience Co., Inc.Zhaoqing Guangdong was founded in 1964 and is based in Zhaoqing, China.
Starlake Bioscience Co Inc Zhaoqing Guangdong management
5- Mr. Xiaolin YanGM & Director · born 1975
- Mr. Jun Lai ChenChief Financial Officer · born 1976
- Mr. Xiaolong YanDeputy GM & Director · born 1973
- Mr. Kaijia ZhangBoard Secretary · born 1984
- Mr. Lijian HuangDeputy General Manager · born 1968